Mill Creek Life Sciences

Executive Summary

Mill Creek Life Sciences is a Seattle-based private company specializing in human platelet lysates (hPL) for cell-based therapies. Founded in 2010, the company's products have been used in over 50 Phase I–III clinical trials globally, supporting thousands of patients. Their hPL formulations are derived from human platelets and have demonstrated safety and efficacy in accelerating cell therapy development. With a focus on diagnostics and digital health, Mill Creek provides a scalable, xeno-free alternative to fetal bovine serum, addressing critical needs in regenerative medicine and immunotherapy. The company is well-positioned to capture growing demand as cell therapies advance toward commercialization, leveraging its decade-long track record and regulatory approvals.

Upcoming Catalysts (preview)

• Q3 2026Publication of Phase II/III trial results for lead hPL formulation75% success
• Q3 2026Strategic partnership with major cell therapy developer65% success
• Q3 2026FDA clearance of expanded indications for existing hPL products80% success